fasudil has been researched along with Cardiomegaly in 11 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
Excerpt | Relevance | Reference |
---|---|---|
"Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 7.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
"In this study, the role of the RhoA/Rho-kinase (RhoA/ROCK)-signaling pathway in cardiovascular dysfunction associated with hyperthyroidism was examined with the use of fasudil, a Rho-kinase inhibitor." | 3.78 | RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism. ( Jianping, Z; Li, C; Na, W; Peng, G; Shengjiang, G; Yanzhong, C, 2012) |
"Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 3.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
"The present study was undertaken to investigate the effect of fasudil, a specific Rho-kinase inhibitor, in pathological cardiac hypertrophy induced by partial abdominal aortic constriction (PAAC) for 4 weeks in comparison with physiological cardiac hypertrophy caused by chronic swimming training (CST) for 8 weeks in rats." | 3.73 | Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. ( Balakumar, P; Singh, M, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (36.36) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zhuang, R | 1 |
Wu, J | 1 |
Lin, F | 1 |
Han, L | 1 |
Liang, X | 1 |
Meng, Q | 1 |
Jiang, Y | 1 |
Wang, Z | 1 |
Yue, A | 1 |
Gu, Y | 1 |
Fan, H | 1 |
Zhou, X | 1 |
Liu, Z | 1 |
Ocaranza, MP | 1 |
Fierro, C | 1 |
Jalil, JE | 1 |
Moya, J | 1 |
Gonzalez, L | 1 |
Molina, C | 1 |
Mancilla, C | 1 |
Yan, X | 1 |
Jiao, K | 1 |
Song, X | 1 |
Ying, Z | 1 |
Yue, P | 1 |
Xu, X | 1 |
Zhong, M | 1 |
Sun, Q | 1 |
Mikolaj, M | 1 |
Wang, A | 1 |
Brook, RD | 1 |
Chen, LC | 1 |
Rajagopalan, S | 1 |
Na, W | 1 |
Peng, G | 1 |
Jianping, Z | 1 |
Yanzhong, C | 1 |
Shengjiang, G | 1 |
Li, C | 1 |
Ho, TJ | 1 |
Huang, CC | 1 |
Huang, CY | 1 |
Lin, WT | 1 |
Satoh, S | 1 |
Kawasaki, K | 1 |
Ikegaki, I | 1 |
Asano, T | 1 |
Shimokawa, H | 1 |
Zhang, ZJ | 1 |
Fan, YF | 1 |
Zhang, ZY | 1 |
Xie, PY | 1 |
Fang, HC | 1 |
Su, YS | 1 |
Wang, YX | 1 |
da Cunha, V | 1 |
Martin-McNulty, B | 1 |
Vincelette, J | 1 |
Li, W | 1 |
Choy, DF | 1 |
Halks-Miller, M | 1 |
Mahmoudi, M | 1 |
Schroeder, M | 1 |
Johns, A | 1 |
Light, DR | 1 |
Dole, WP | 1 |
Balakumar, P | 1 |
Singh, M | 1 |
McKinsey, TA | 1 |
Kass, DA | 1 |
1 review available for fasudil and Cardiomegaly
Article | Year |
---|---|
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomegaly; Cardiovascular Agents; | 2007 |
10 other studies available for fasudil and Cardiomegaly
Article | Year |
---|---|
Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cell Line; Heart Diseases; Hum | 2018 |
Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Remodeling; Blood Pressure; Cardiomeg | 2018 |
Shen'ge powder decreases the cardiomyocyte hypertrophy in chronic heart failure by activating the Rho protein/Rho-associated coiledcoil forming protein kinase signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Cardiomegaly; Cell Survival; Dise | 2019 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; bcl-2-Associated X Protein; Cardi | 2012 |
Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bi | 2012 |
Evidence of a direct cellular protective effect of Rho-kinase inhibitors on endothelin-induced cardiac myocyte hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cells, Cultured; Cytoprotectio | 2012 |
[Effects of rho-kinase inhibitor on cardiac hypertrophy of left ventricle in spontaneously hypertensive rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Heart Ventricles; Male; Nifedi | 2012 |
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Apolipoproteins E; Atrial Na | 2005 |
Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adaptation, Physiological; Animals; Blood Pressure; C | 2006 |